ERBB2 and breast carcinoma: There is no clinical data about Afatinib on HER2-negative breast cancer because the randomized clinical trial, TRIO-020, which was supposed to evaluate Afatinib efficacy on HER2-negative breast cancer, was discontinued (74, 75).